fda changes to semaglutide just got FDA-approved for kidney disease. This everything., January 2025. The approved semaglutide (Ozempic/Wegovy) for a new indication: reducing kidney disease progression in FDA alerts health care providers,

Kong R, Ji L, Pang Y, Zhao D, Gao J

Chronic inflammation is a key factor in the development of many diseases, including Type 2 diabetes Cardiovascular disease Some Trusted Source Risk Factors: Chronic Inflammation National Cancer Institute Go to Source cancers Lifestyle modifications like diet and exercise are the cornerstone of obesity management, but GLP-1 can make a huge difference

BMI, body mass index (calculated as weight in kilograms divided by height in meters squared)

Partial deletion of the cAMP response element-binding protein gene promotes alcohol-drinking behaviors

Data availability All data are included either in manuscript or in suplementary information file